Fairfax, Va. (November 28, 2017) —Virginia Cancer Specialists (VCS) announced that Stephanie Akbari, MD, FACS, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.
Dr. Akbari, the first dedicated breast surgeon in Northern Virginia, has been practicing in the area since 2001. Continually integrating new and innovative technology into treatments, Dr. Akbari established the first nationally accredited breast cancer center in the Washington, D.C., region in 2007. There, Dr. Akbari became the first in the area to become certified in breast ultrasound, incorporate partial breast irradiation, and perform office-based minimally invasive breast biopsies.
“We are delighted to have Dr. Akbari, a true leader in the field in breast cancer treatment, join our growing practice,” said Linda Anderson, executive director of VCS. “With her vision and focus on promising new advancements in breast cancer treatment, Dr. Akbari is a welcome addition to the treatment team as we seek to deliver the very best in cancer care to the Northern Virginia community.”
“It is very exciting to join Virginia Cancer Specialists,” said Dr. Akbari. “Throughout my career, I have admired VCS’s cutting-edge and integrated approach to treating cancer patients. I am thrilled to join this incredible team of professionals dedicated to providing comprehensive breast cancer care, one that has such a long-standing, strong commitment to research.”
Dr. Akbari earned her undergraduate degree from Mount Holyoke College. She received her medical training at the University of Pennsylvania and completed her residency in surgery at Harvard’s New England Deaconess Hospital. She is a fellow of the American College of Surgeons and a member of the American Society of Breast Surgeons, previously serving on committees of both organizations. Since 2005, Dr. Akbari has been recognized as one of the region’s “Top Docs” in breast surgery by Washingtonian Magazine.
About Virginia Cancer Specialists
For more than 40 years, Virginia Cancer Specialists (VCS) has contributed to the campaign against cancer and diseases of the blood. VCS has nine locations throughout Northern Virginia staffed by highly-skilled physicians, each delivering exceptional care. The practice has built a world-class treatment team of cancer specialists, as well as acquiring the very latest treatment technology to help achieve the best outcomes for patients. VCS unites medical and radiation oncologists, breast and musculoskeletal surgeons, hematologists, palliative care physicians, oncology nurse navigators, oncology infusion nurses, radiation therapists, genetic counselors, oncology pharmacists and laboratory technicians. All working together, this team designs the optimal multidisciplinary treatment program, efficiently shares knowledge, executes the treatment plan, and provides a patient-centered, consumer-friendly approach to cancer care. Patients receive the full spectrum of high-quality care necessary to treat their disease from a care team united in their effort to provide each patient with the specific personalized care they need to battle cancer. The physicians at VCS have published more than 100 abstracts and papers over the last few years and have been invited to present at national meetings. To learn more about Virginia Cancer Specialists, please visit www.VirginiaCancerSpecialists.com.
Virginia Cancer Specialists is an affiliate of The US Oncology Network (The Network). This collaboration unites VCS with more than 1,400 independent physicians dedicated to delivering value-based, integrated care for patients—close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The US Oncology Network is supported by McKesson Specialty Health, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices. VCS also participates in clinical trials through US Oncology Research, which has played a role in more than 70 FDA-approved cancer therapies, approximately one-third of all cancer therapies approved by the FDA to date. For more information, visit www.usoncology.com.
Michelle Keene, Virginia Cancer Specialists
Claire Crye, The US Oncology Network